Investigational drug · Phase 2
TTYP01
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Autism Spectrum Disorder (ASD).
Phase 2Last checked: Nov 19, 2026Latest source record: May 14, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
5
Any phase or sponsor naming "TTYP01"
First trial start
2025
Jan 13, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "TTYP01", any sponsor or status.
Conditions studied
As listed on its trial records.
- Autism Spectrum Disorder (ASD)
Largest trials
Live from ClinicalTrials.gov: studies naming "TTYP01" as an intervention, largest first.
- Evaluate the Efficacy and Safety of TTYP01 Tablets in the Treatment of Acute Ischemic StrokePivotal-lookingCompleted
Shanghai Auzone Biological Technology Co., Ltd.Industry
NCT06648304 · 614 participants · Start Apr 25, 2023 · Primary completion Jun 17, 2024
Drug: TTYP01 tablets; Placebo (Simulant TTYP01 Tablets) · For: Acute Ischemic Stroke
Sites: Chongqing, China
- A Study to Evaluate the Efficacy and Safety of TTYP01 Tablets in Early Symptomatic Alzheimer's DiseasePivotal-lookingRecruiting
Shanghai Auzone Biological Technology Co., Ltd.Industry
NCT07252440 · 180 participants (planned) · Start Dec 19, 2025 · Primary completion Oct 23, 2028
Drug: TTYP01 tables 60mg; TTYP01 tables 90mg and 1 more · For: AD; Early Alzheimer's Disease
Sites: Chongqing, China
- Evaluate the Efficacy and Safety of TTYP01 Tablets in Adolescents and Children With ASDPivotal-lookingRecruiting
Shanghai Auzone Biological Technology Co., Ltd.Industry
NCT06757504 · 150 participants (planned) · Start Jan 13, 2025 · Primary completion Feb 6, 2026
Drug: TTYP01 Tablets (12mg or 18mg); Placebo (Simulant TTYP01 Tablets) · For: Autism Spectrum Disorder (ASD)
Sites: Beijing, China; Changsha, China; Chengdu, China · 5 sites in all
Shanghai Auzone Biological Technology Co., Ltd.Industry
NCT04370431 · 72 participants · Start Apr 24, 2020 · Primary completion Dec 17, 2020
Drug: TTYP01 single ascending doses; Placebo and 5 more · For: Healthy Adult Subjects
Sites: Adelaide, Australia
Shanghai Auzone Biological Technology Co., Ltd.Industry
NCT06107205 · 29 participants · Start Nov 7, 2023 · Primary completion Dec 14, 2023
Drug: TTYP01; Radicava and 1 more · For: Healthy Adult Subjects
Sites: San Antonio, Texas
Newest research
PubMed records naming it or its code names, newest first.
- Early and prolonged oral edaravone for neuroprotection in acute ischemic stroke: the ERASE-STROKE randomized controlled phase 3 trial.
Xiang Y, Jin WS, Zhu XC, et al. · Sci Bull (Beijing) 2026
Also in development for Autism Spectrum Disorder (ASD)
- SPG601CodabakalnerPhase 32 trials
Spinogenix · Fragile X Syndrome (FXS), Autism Spectrum Disorder (ASD), Fragile X Syndrome
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.